Rxi Pharmaceuticals Corporation (NASDAQ:RXII) Just Reported Increased Shorts

June 8, 2018 - By Maria Brooks

RXi Pharmaceuticals Corporation (NASDAQ:RXII) Logo

The stock of Rxi Pharmaceuticals Corporation (NASDAQ:RXII) registered an increase of 17.01% in short interest. RXII’s total short interest was 387,300 shares in June as published by FINRA. Its up 17.01% from 331,000 shares, reported previously. With 240,400 shares average volume, it will take short sellers 2 days to cover their RXII’s short positions. The short interest to Rxi Pharmaceuticals Corporation’s float is 20.11%.

The stock decreased 2.85% or $0.07 during the last trading session, reaching $2.39. About 76,041 shares traded. RXi Pharmaceuticals Corporation (NASDAQ:RXII) has declined 59.82% since June 8, 2017 and is downtrending. It has underperformed by 72.39% the S&P500.

RXi Pharmaceuticals Corporation, a clinical-stage company, focuses on developing therapeutics for unmet medical needs. The company has market cap of $10.17 million. It develops therapies based on its self-delivering RNAi platform; and Samcyprone topical immunomodulatory. It currently has negative earnings. The companyÂ’s clinical development programs include RXI-109, an sd-rxRNA compound, which is in Phase II clinical trial for preventing or reducing dermal scarring following scar revision surgery of an existing hypertrophic scar; and in Phase I/II clinical trial for treating retinal scarring, as well as in discovery stage for the treatment of corneal scarring.

More important recent RXi Pharmaceuticals Corporation (NASDAQ:RXII) news were published by: Streetinsider.com which released: “RXI Pharma (RXII) Reports Positive Results from Phase 2 Trial with Samcyprone for Treatment of Common Warts” on May 18, 2018, also Seekingalpha.com published article titled: “RXI Pharmaceuticals’ (RXII) CEO Geert Cauwenbergh on Q1 2018 Results – Earnings Call Transcript”, Streetinsider.com published: “RXI Pharma (RXII) Enters Pact With Iovance Bio (IOVA) to Study its Self-Delivering RNAi Technology” on May 11, 2018. More interesting news about RXi Pharmaceuticals Corporation (NASDAQ:RXII) was released by: Seekingalpha.com and their article: “Key events next week – healthcare” with publication date: May 11, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: